FY2025 Earnings Forecast for Allogene Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Investment analysts at Zacks Research issued their FY2025 earnings per share (EPS) estimates for Allogene Therapeutics in a report released on Tuesday, March 14th. Zacks Research analyst S. Ganoria anticipates that the company will earn ($2.61) per share for the year. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($2.57) per share.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last released its earnings results on Tuesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.05. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.06 million. Allogene Therapeutics had a negative return on equity of 43.44% and a negative net margin of 136,885.59%. Allogene Therapeutics’s revenue was down 6.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.54) earnings per share.

A number of other brokerages also recently weighed in on ALLO. JPMorgan Chase & Co. raised Allogene Therapeutics from a “neutral” rating to an “overweight” rating and reduced their target price for the company from $20.00 to $11.00 in a report on Tuesday, January 24th. JMP Securities lowered their price objective on Allogene Therapeutics from $23.00 to $19.00 and set a “market perform” rating for the company in a research report on Thursday, March 2nd. Bank of America downgraded Allogene Therapeutics from a “buy” rating to an “underperform” rating and cut their price target for the company from $24.00 to $9.00 in a research note on Monday, December 12th. B. Riley cut their price target on Allogene Therapeutics from $18.00 to $15.00 in a research note on Wednesday, March 1st. Finally, Robert W. Baird upgraded Allogene Therapeutics from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research note on Friday, January 6th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Allogene Therapeutics Trading Down 2.7 %

Shares of NASDAQ ALLO opened at $5.51 on Thursday. The firm has a market cap of $796.20 million, a P/E ratio of -2.38 and a beta of 0.81. Allogene Therapeutics has a 1-year low of $5.36 and a 1-year high of $17.49. The business’s 50 day moving average is $6.77 and its 200-day moving average is $8.97.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently made changes to their positions in ALLO. CI Investments Inc. boosted its holdings in Allogene Therapeutics by 80.5% in the second quarter. CI Investments Inc. now owns 2,193 shares of the company’s stock worth $25,000 after purchasing an additional 978 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in Allogene Therapeutics by 9.7% in the third quarter. Rockefeller Capital Management L.P. now owns 14,083 shares of the company’s stock worth $151,000 after acquiring an additional 1,248 shares during the period. ProShare Advisors LLC raised its position in Allogene Therapeutics by 6.2% in the fourth quarter. ProShare Advisors LLC now owns 22,181 shares of the company’s stock worth $140,000 after acquiring an additional 1,297 shares during the period. Oppenheimer & Co. Inc. raised its position in Allogene Therapeutics by 10.0% in the second quarter. Oppenheimer & Co. Inc. now owns 16,550 shares of the company’s stock worth $189,000 after acquiring an additional 1,500 shares during the period. Finally, MetLife Investment Management LLC raised its position in Allogene Therapeutics by 4.1% in the third quarter. MetLife Investment Management LLC now owns 42,018 shares of the company’s stock worth $454,000 after acquiring an additional 1,668 shares during the period. Hedge funds and other institutional investors own 72.94% of the company’s stock.

About Allogene Therapeutics

(Get Rating)

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.